Theme: Advances in Infectious Diseases and future trends in antimicrobial
Antibiotics Resistance 2021
Antibiotics Resistance 2021 invites all the participants from all over the world to attend “7th International Conference on Antibiotics & Antibiotic Resistance’’ scheduled to be held on November 12-13, 2021 we are going to conduct this conference at Vancouver, Bahamas . The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Antibiotics Resistance. The primary objective of this meeting is to compile researchers involved in antibiotic resistance prevention and control. The meeting will take a unified approach to research and it will bring about researchers specializing in different subjects related to antibiotic resistance.
Conference Series Ltd organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Antibiotics Resistance 2021 is a platform to discuss and learn about the latest advancements in the field of Antibiotics and Antibiotic Resistance as the world’s consideration turned regarding the urgency of new antibiotics as the antimicrobial resistance is growing day by day. Many developed nations and International health organizations are trying to focus of the current situation and making new policies to prevent the adverse effects of Antibiotic resistance.
This conference gathers researchers, academia, labs, Drug Manufacturers, government agencies, health professionals, hospitals, young investigators, pharma and labs and presents their opinions through key notes, and case study presentations. This conference lays a platform for all the researchers working in the field of Antibiotics to know the latest developments and the current situation of the
- 300+ Participation (70 Industry: 30 Academia)
- 10+ Keynote Speakers
- 50+ Plenary Speakers
- 20+ Exhibitors
- 14 Innovative Educational Sessions
- 5+ Workshops
- B2B Meetings
- Healthcare Students, Scientists, and professors
- Bacteriology Researchers
- Faculty of bacteriology and infectious diseases
- Medical Colleges
- Healthcare Associations and Societies
- Business Entrepreneurs
- Directors, CEO’s of Organizations
- Business Development Managers
- Speaker Presentations
- Poster Display
- Symposium hosting (4-5 member team)
- Workshop organizing
- For Researchers and Faculty Members
For Universities, Associations & Societies:
- Association Partnering
- Collaboration proposals
- Academic Partnering
- Group Participation
For Students and Research Scholars
- Poster Competition (Winner will get Best Poster Award)
- Young Researcher Forum (YRF Award to the best presenter)
- Student Attendee
- Group Registrations
For Business Delegates
- Speaker Presentations
- Symposium hosting
- Book Launch event
- Networking opportunities
- Audience participation
For Product Manufacturers
- Exhibitor and Vendor Booths
- Sponsorships opportunities
- Product launch
- Workshop organizing
- Scientific Partnering
- Marketing and Networking with clients
Track 1: Antibiotics
Antibiotics are a type of antimicrobials that are used in treatment and prevention of bacterial infections. They may kill or inhibit the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to humans and animals also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as common cold or influenza, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics.
Track 2: Antibiotic Resistance:
Opportunities and Challenges Certain bacterial infections now oppose all antibiotics. The resistance problem may be reversible, but only if society begins to acknowledge how the drugs affect "good" bacteria as well as "bad". Historically, most antibacterials were used in hospitals, where they were integrated into surgical clothes and soaps to limit the spread of infection. More recently, however, those substances (including triclosan, triclocarbon and such quaternary ammonium compounds as benzalkonium chloride) have been mixed into lotions, dish-washing detergents and soaps meant for general consumers. They have also been impregnated into such items as cutting boards, toys, high chairs and mattress pads.
Track 3: Antibiotics in Different Industries
Antibiotics must be used accordingly in humans and animals because both uses share to the emergence, persistence, and escalation of resistant bacteria. Resistant bacteria in food-producing animals are of particular concern. Food animals play as a source of resistant pathogens and resistance mechanisms that can directly or indirectly result in antibiotic resistant infections in humans. Resistant bacteria may be transmitted to humans through the foods we eat. Some bacteria have turned resistant to more than one sort of antibiotic, which makes it more difficult to treat the infections they cause. Sustaining the efficiency of antibiotic drugs is vital to insulating human and animal health.
Environmental microbes are a leading source of drug discovery, and several microbial products ( anti-tumour products, antibiotics, immunosuppressants and others) are used frequently for human therapies. Most of these products were accessed from cultivable (<1%) environmental microbes, means that the large number of microbes were not targeted for drug discovery. With the onset of new and emerging technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microbes. Multidisciplinary way of linking different technologies can assist and reform drug discovery from uncultivable microbes and inspect the current cramp of technologies and scenario to swamped such constraints that might further expand the promise of drugs from environmental microbes.
Track 5: Clinical Trials of Antibiotics
Prescribing doctors are, progressively, using clinical trial data as a major source of information for evidence-based medicine for the remedy of infectious diseases, as in other clinical disciplines. However, it may be difficult to excerpt from these data the material that is needed for the management of the individual patient. At the same time, clinical trial testimony have been used, probably satisfactorily, in the process of drug registration, and the pharmaceutical industry has spent progressively large amount of money to satisfy the needs of this process. In the face of all these problems, switch in the way antibiotic clinical trials are designed and performed are clearly necessary, although this must not disturb the balance so far as to restore them less useful for those who currently derive greatest benefit from them.
The discovery of a new antibiotic called teixobactin was announced by international team of researchers, in January this year. It is the most significant new antibiotic to be discovered in more than 30 years, and it may help combat the growing number of drug-resistant bacteria.
Track 7: Alternative to Antibiotics
This new method uses the enzymes of bacteriophages to attack the bacteria. Bacteriophages are tiny viruses that infect bacteria. After they infect the bacteria, they replicate or make copies of themselves, and then leave the bacteria to go and infect other bacteria. To be able to leave the bacteria, the "phages" make an enzyme that dissolves the wall of the bacterial cell, thus killing it.
The world is in the midst of an emerging crisis of antibiotic resistance to microbial pathogens. Numerous pathogens that have become resistant to commonly used antibiotics have been described in various contexts, including drug-resistant methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumonia, and Mycobacterium tuberculosis. Considering the breadth of effect and significant impact on morbidity and mortality, multi-drug-resistant (MDR) pathogens are a substantial threat to public health. Although this problem calls for the development of new antibiotics with new mechanisms of action, the pharmaceutical industry has abandoned the sector as less lucrative for their investments. The number of new antibiotics approved by the U.S. Food and Drug Administration (FDA) declined dramatically during the past 2 decades.
Increasing drug resistance is caused primarily by inappropriate use of antimicrobials in humans as well as in animals, and spread of resistant strains between the two. Antibiotics develop selective pressure in bacterial strength, resulting accessible bacteria to die; this enhances the percentage of resistant bacteria which continue increasing. With resistance to antibiotics becoming more common there is greater need for alternative treatments. New antibiotic therapies have been needed, but new drug developmentis becoming scarce. A World Health Organization (WHO) report released April 2014 stated, "This serious threat is no longer a prediction for the future, it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country. Antibiotic resistancewhen bacteria change so antibiotics no longer work in people who need them to treat infections is now a major threat to public health. Increasing public calls for global collective action to address the threat include proposals for international treaties on antimicrobial resistance.
Bacteria can acquire antibiotic resistance genes from other bacteria in several ways. By undergoing a simple mating process called "conjugation," bacteria can transfer genetic material, including genes encoding resistance to antibiotics (found on plasmids and transposons) from one bacterium to another. Antibiotic resistance genes have been identified in diverse environments including soil, gull feces and, increasingly, in the human gut microbiota. Scientists have applied a range of approaches to detect antibiotic resistance genes in environmental or non-clinical microbiomes, all of which have their own inherent strengths/limitations. Proteomic studies have improved our understanding of the microbial world. The most recent advances in this field have helped us to explore aspects beyond genomics. Proteomics has also advanced our knowledge of mechanisms of bacterial virulence and some important aspects of how bacteria interact with human cells and, thus, of the pathogenesis of infectious diseases. We have used proteomic technology to elucidate the complex cellular responses of Bacillus subtilis to antimicrobial compounds belonging to classical and emerging antibiotic classes.
The use of antimicrobials in animals closely parallels their discovery and usage in humans. Sulfonamide was the first antimicrobial to be introduced to food animal medicine in the 1940s. Antimicrobial resistance emerges from the use of antimicrobials in animals and the subsequent transfer of resistance genes and bacteria among animals and animal products and the environment. Antibiotics are also given to food animals for growth promotion and prophylactic medication. In 2011, a total of 13.6 million kilograms of antimicrobials were sold for use in food-producing animals in the United States, which represents 80% of all antibiotics sold or distributed in the United States. Of the antibiotics given to animals from 2009 through 2013, just above 60% distributed for food animal use are "medically-important" drugs, that are also used in humans. The rest are drug classes like ionophores which are not used in human medicine. here are also global concerns over the use of antibiotics for growth promotion or therapy purposes because of the potential for some drugs to enter the human food chain despite rigorous withdrawal measures and testing to prevent antibiotic residues in food, increasing antibiotic resistance in animals, a potential although largely unproven link to antibiotic-resistant infections in humans, and what some consider antibiotic misuse. When government regulation restricts use of antibiotics the negative economic impact is not often considered.
There is a renewed interest in the antibiotic sector, which is evident from the most recent patents and investments. Bacterial vaccines and new antibiotic classes are gaining a tremendous amount of attention with several product candidates in clinical development. These new products are expected to change the outlook of the antibiotic sector to a large extent over the next 5 years. Several reports focus on anti-infective markets in general. This report, however, focuses exclusively on antibacterials, with a particular emphasis on the emerging problem of antibiotic resistance. It also includes a detailed analysis of the emerging technology trends, which give a clear picture of the future of the sector. This helps to provide regulatory authorities and industry strategists a better perspective on which to base their decisions. BCC Research published a report on this topic in 2002. Since then, the market has witnessed dramatic changes in terms of technology, investment, and regulatory trends, which are captured in this report.
Track 13: Antimicrobial Resistance
Public Health Concerns This topic reviews the global antibiotic markets, including discussions on the market development and growth potential over the next 5 years. It also analyses key factors that are driving the market growth. It describes the trends in detail with respect to various antibiotic classes, including the novel classes that are emerging and their technological basis. It includes in-depth discussions of the industry structure and the regulatory environment. It is valuable reading for investors, policymakers, and industry participants. Profiles of leading players in the industry are also included. Such involved analyses have been conducted to help strategy developers and decision makers within pharmaceutical companies and government bodies. The detailed analyses of the regulatory factors that play major roles in deciding the industry trends are especially useful for legislators involved in government policy development programs. Technology trend and patent analyses give an overview of the new trends with respect to innovation within the sector.
In the time since penicillin was discovered nearly 80 years ago, antibiotics have become one of the most important lifesaving weapons in doctors' arsenal against bacterial infection. Now, the Lakeland, Fla.-based Publix grocery store chain is giving away seven of these drugs free of charge to those who have prescriptions for them. Five of these are amoxicillin, ampicillin, cephalexin, erythromycin and penicillin VK -- are commonly used by doctors to treat bacterial infections ranging from ear infections to gonorrhea. But two of the drugs on the list -- ciprofloxacin and sulfamethoxazole/trimethoprim -- are high-grade antibiotics that doctors usually reserve for particularly serious infections. While some hail the program as a godsend, others fear that the move could lead to overuse of the drugs. This is because the use of antibiotics comes attached with important considerations. According to the American Academy of Family Physicians, there are certain situations in which antibiotics are helpful -- and many in which they can cause more harm than good. Penicillins, Cephalosporins, Aminoglycosides, Glycopeptides, Tetracyclines are antibiotics most commonly showing side effects.
The analysis of antibiotic susceptibility disks by high-pressure liquid chromatography (HPLC) methods are presented for the potency determination of mecillinam, ampicillin, carbenicillin, and cephalotjiin alone and in various combinations. Good agreement between HPLC and microbiological data is observed for potency determinations with recoveries of greater than 95%. Relative standard deviations of lower than 2% are recorded for each HPLC method. HPLC methods offer improved accuracy and greater precision when compared to the standard microbiological methods of analysis for susceptibility disks. The most popular analytical methods for the determination of beta-lactams are the chromatographic ones, including high performance liquid-chromatography (HPLC) and thin layer chromatography (TLC). HPLC offers high sensitivity and separation efficiency, establishing itself as the first choice method for the analysis of beta-lactams; however it is expensive and requires sophisticated equipment. TLC is a less expensive and less complicated chromatographic procedure, which can be successfully used, in the preliminary screening of pharmaceutical substances. In modern analysis, TLC is usually used as a separation method, which establishes the presence or absence of beta-lactam antibiotics above a defined level of concentration.
Antibiotics have been applied for the treatment of autoimmune diseases for over five decades, based on the premise that infections play a role in the initiation and propagation of these entities. The antibiotics market was valued at USD 39.8 million in 2015 and is expected to witness a CAGR of 4.0% over the forecast period. Increasing efforts are being witnessed toward the development of advanced products. According to the data published by the Pew Charitable Trust, in March 2016, about 37 promising molecules were being investigated within the U.S. market. Majority of these, are in phase II clinical trials and are anticipated to hit the market between 2018 - 2020. Furthermore, supportive government legislations, such as the Generating Antibiotics Incentives Now (GAIN) Act are expected to expedite the approval process. GAIN Act has provisions which facilitate development of therapy against antibiotic resistant pathogens.
The anti-microbials showcase is required to achieve USD 57.0 billion by 2024, as indicated by the new report by Grand View Research, Inc. Rising pervasiveness of irresistible illnesses particularly in creating locales, for example, Asia Pacific and MEA is foreseen to contribute towards showcase development.
Over 15.0% of the passings, in kids underneath the age of five, are assessed to be because of pneumonia and as indicated by the insights given by the WHO around 9.2 million passings were recorded in 2015. Like tuberculosis, the most elevated commonness of the sickness is recognized to be in the South Asian and Sub-Saharan locales. At present, the required anti-infection treatment is accessible just to 33% of the tainted populace, subsequently expanding the illness trouble.
Government changes particular to anti-microbials, for example, the Generating Antibiotics Incentives Now (GAIN) Act in the U.S. are anticipated to help showcase development over the conjecture time frame. This further expected encourage improvement of cutting edge drugs.
Unexpectedly, unverifiable administrative approaches are probably going to impede the development of this vertical affecting business sector development fundamentally. In 2013, the U.S. FDA changed the direction for enlistment preliminaries for drugs utilized in the treatment of intense bacterial skin and skin structure contaminations. The direction expresses the utilization of here and now proportions of hostile to infective adequacy (percent decrease in sore size at 48 to 72 hours) instead of long haul estimates, for example, goals of contamination at 10-14 days, which is named as Test to Cure or TOC.
Additionally Key Findings From the Study Suggest:
Antibiotic fragment including antibiotic medications, imidazoles, lincosamides and monoclonal antibodies held ordering share in 2015 and are additionally foreseen to develop at a lucrative development rate over the estimate time frame
Development of monoclonal antibodies for anti-infection safe microorganism is key feature of this fragment. Expanding frequencies of pneumonia, circulatory system diseases, and urinary tract contaminations (UTI) are foreseen to cultivate the use of carbapenems class of anti-infection agents.
Planning a Trip to Vancouver, Canada!Attending Meeting!!!
An issue with VISA!!
Antibiotic Resistance Committee will be happy to help you in all regards to plan your trip to Vancouver, Canada. Avail the official invitation letter from us to attend this event ahead with a closer step for approval of your VISA.
Find out what you need to do to visit Canada as a tourist or business person, how to extend your stay in Canada and what documents you need to carry with you to transit through Canada.
Canada does not have a visa office in every country so it is important that Delegates/Attendees visit the website of the visa office responsible for processing their visa applications. Information is available on the website on how to submit a visa application and the documentation required.
This system allows clients to submit applications online.
Delegates/Attendees that need a visa but require their passport for other travel purposes are strongly encouraged to submit their visa applications online (e-Apps).Delegates/Attendees that choose to apply online will not have to submit their passport until a decision has been taken on their applications. If required, the visa office will send the applicant instructions on how and where to send their passports to finalize the visa process.
Visa Application Centres (VACs):
VACs are commercial service providers authorized by Canada to provide specific services to applicants.
VACs provide a number of services including help applicants fill out forms, answer questions and ensure that applications are complete, thereby reducing unnecessary delays or refusals due to incomplete applications.
Applicants that are required to provide biometrics information as part of the visa application process can do so at a VAC. Additional information on the biometrics requirements is available at the IRCC website.
VACs send applications to Visa Offices and transmit decisions to applicants in a secure and confidential manner. VACs do not process visa applications and play no role in the decision-making process.
Visa Applications Processing Time:
Processing time for visa applications vary depending on the office and the time of the year. Participants should be encouraged to apply early for their visas, and to submit complete applications including all supporting documents.
Please visit the IRCC website for information on the time it takes to process visa applications at the various visa offices.
NEW - Electronic Travel Authorization (eTA)
As of March 15, 2016, visa-exempt foreign nationals are expected to have an Electronic Travel Authorization (eTA) to fly to or transit through Canada. Exceptions include U.S. citizens and travelers with a valid Canadian visa. Canadian citizens, including dual citizens, and Canadian permanent residents are not eligible to apply for an eTA.
However, from March 15, 2016, until fall 2016, travellers who do not have an eTA can board their flight, as long as they have appropriate travel documents, such as a valid passport. During this time, border services officers can let travellers arriving without an eTA into the country, as long as they meet the other requirements to enter Canada. We invite you to consult the IRCC website regularly for information updates on eTA.
Best Tourist Destination:
- Vancouver Stanley
- Park Granville Island
- Grouse Mountain
- Museum of Anthropology
- Kitsilano Beach
- Canada Place
- English Bay
- Capilano Suspension Bridge
- Robson Street
- Museum of Vancouver
- Queen Elizabeth Park
- Science World Richmond & Many more…
- Discovery of Antibiotics
- Pharmacology of Antibiotics
- Different Types of Antibiotics
- Antibiotics for Emerging and Re-Emerging Diseases
- The Emergence of Antimicrobial Resistance
- Antibiotics for Various Diseases and Infections
- Antimicrobial Resistance
- Antibiotics for Various Diseases and Infections
- Antibiotic Shortage: A Serious Safety Concern
- Antibiotics in Different Industries
- Micro Organisms in Recent Drug Discovery
- Drug Discovery and Novel Delivery Technologies
- Clinical Trials of Antibiotics
- Antibiotics and Mechanism of Action
- Antibiotics: Market Analysis & Business Opportunities
To share your views and research, please click here to register for the Conference.